RhoA with Associated TRAb or FT3 in the Diagnosis and Prediction of Graves' Ophthalmopathy.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
12
2021
revised:
18
05
2022
accepted:
01
07
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
10
8
2022
Statut:
epublish
Résumé
During Graves' disease (GD) treatment, Graves' ophthalmopathy (GO) is often ignored because only mild ocular symptoms are present in early GD. Therefore, we performed isobaric tags for relative and absolute quantification (iTRAQ) analysis and measured relevant endocrine hormones to identify predisposing factors of GO. Serum samples from 3 patients with mild GD and GO and 3 patients with GD but without GO were analyzed by iTRAQ. Based on their clinical data, 60 patients with GD were divided into the GO-free and GO groups. All patients were followed up for 7 months. Their eye conditions and changes in related biochemical indexes were recorded. The iTRAQ results showed that RhoA expression was upregulated and correlated significantly with the tight junction pathway and immunity. The changes in FT3 and RhoA from baseline to 7 months, the FT3 and RhoA baseline levels, and the TRAb titer levels in patients with GD significantly differed between the groups. ELISA and western blotting for RhoA, TRAb, and FT3 in the serum samples from GO patients showed significant upregulation, as well as elevated serum RhoA and TRAb levels in the mild stage of GO. At 7 months, the serum RhoA and FT3 levels were elevated. RhoA is a potential biomarker for mild GO. In GD patients, if an elevated serum RhoA level is accompanied by an elevated TRAb or FT3 level, GO is highly likely to occur, even when obvious ocular symptoms are absent.
Identifiants
pubmed: 35937945
doi: 10.1155/2022/8323946
pmc: PMC9355757
doi:
Substances chimiques
Biomarkers
0
RHOA protein, human
124671-05-2
rhoA GTP-Binding Protein
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8323946Informations de copyright
Copyright © 2022 Sidi Zhao et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
N Engl J Med. 1993 Nov 11;329(20):1468-75
pubmed: 8413459
J Proteome Res. 2010 Apr 5;9(4):1923-30
pubmed: 20121168
Cent Eur J Immunol. 2014;39(2):216-22
pubmed: 26155127
J Clin Endocrinol Metab. 2006 Sep;91(9):3464-70
pubmed: 16835285
Eur J Endocrinol. 2008 Mar;158(3):273-85
pubmed: 18299459
Front Immunol. 2017 May 09;8:521
pubmed: 28536577
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
J Endocrinol Invest. 2013 Jun;36(6):444-9
pubmed: 23587873
Int J Mol Med. 2006 May;17(5):911-6
pubmed: 16596280
Front Endocrinol (Lausanne). 2021 Feb 01;11:607968
pubmed: 33597925
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14717-24
pubmed: 26823796
Curr Opin Ophthalmol. 2021 May 1;32(3):268-274
pubmed: 33606407
Am J Ophthalmol. 1995 Jun;119(6):792-5
pubmed: 7785696
Turk J Ophthalmol. 2017 Apr;47(2):94-105
pubmed: 28405484
Cells. 2019 Jul 17;8(7):
pubmed: 31319592
J Transl Med. 2018 Jul 5;16(1):188
pubmed: 29976201
Immunol Rev. 2010 Nov;238(1):247-62
pubmed: 20969597
J Intern Med. 2015 Oct;278(4):369-95
pubmed: 26212387
Horm Metab Res. 2018 Dec;50(12):908-921
pubmed: 30360003
J Proteome Res. 2019 Dec 6;18(12):4085-4097
pubmed: 31573204
Acta Med Indones. 2017 Jul;49(3):195-204
pubmed: 29093229
Endocr Rev. 2019 Feb 1;40(1):236-267
pubmed: 30215690
Exp Clin Endocrinol Diabetes. 2014 Jan;122(1):1-6
pubmed: 24203649
Ophthalmology. 2012 Mar;119(3):625-8
pubmed: 22197435
Methods Mol Biol. 2017;1514:19-30
pubmed: 27787789
J Exp Clin Cancer Res. 2009 Aug 28;28:122
pubmed: 19715608
Nat Rev Immunol. 2002 Feb;2(2):116-26
pubmed: 11910893
Thyroid. 2010 Jan;20(1):59-65
pubmed: 20017620
Thyroid. 2015 Mar;25(3):347-51
pubmed: 25584927
Int J Ophthalmol. 2011;4(6):652-7
pubmed: 22553739
Nat Rev Endocrinol. 2013 Dec;9(12):724-34
pubmed: 24126481
N Engl J Med. 2010 Feb 25;362(8):726-38
pubmed: 20181974
Thyroid. 2007 Oct;17(10):1013-8
pubmed: 17935483
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6843-6851
pubmed: 28002844
J Clin Endocrinol Metab. 2009 Oct;94(10):3700-7
pubmed: 19723755
Yonsei Med J. 2013 Jul;54(4):1033-9
pubmed: 23709442
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:129-148
pubmed: 30044728
Annu Rev Immunol. 2001;19:225-52
pubmed: 11244036
Acta Med Indones. 2012 Apr;44(2):114-21
pubmed: 22745141
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
Clin Exp Immunol. 1989 Feb;75(2):222-7
pubmed: 2784734
Prog Retin Eye Res. 2015 Nov;49:17-45
pubmed: 26197361